Semler Scientific Q2 revenue beats estimates
Overview
Semler Scientific Q2 revenue declines 43% yr/yr, beats analyst expectations, per LSEG data
Net income for Q2 rises to $66.9 mln, driven by Bitcoin gains
Company achieves 29% BTC yield in Q2, launches CardioVanta subsidiary during Q2
Outlook
Company continues to focus on Bitcoin treasury strategy
Semler Scientific emphasizes growth in healthcare via CardioVanta
Company does not provide specific future financial guidance in its press release
Result Drivers
BITCOIN STRATEGY - Unrealized gains from Bitcoin holdings significantly boosted net income
CARDIOVANTA LAUNCH - Launch of CardioVanta subsidiary aims to drive future healthcare initiatives
INCREASED EXPENSES - Operating expenses rose due to stock-based compensation and legal costs related to U.S. Department of Justice investigation
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $8.22 mln | $8.10 mln (2 Analysts) |
Q2 EPS |
| $5.04 |
|
Q2 Basic EPS |
| $5.71 |
|
Q2 Income From Operations |
| -$2.05 mln |
|
Q2 Operating Expenses |
| $10.27 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Semler Scientific Inc is $98.00, about 64.8% above its August 1 closing price of $34.46
Press Release: ID:nPn8631kQa
